Home > Reports > Plasma Fractionation Market Size, share and Growth Forecast 2030 | Straitsresearch

Plasma Fractionation Market

Plasma Fractionation Market: Information by Product (Albumin, Immunoglobulins), Sector (Public Sector, Private Sector), and Region — Forecast till 2030

Published On : 19 Jul, 2022
Updated On : 14 Nov, 2022
Table of Content Download Sample

Market Snapshot

Base Year:
2021
Study Period:
2020-2030
CAGR:
6.5 %
Fastest Growing Market:
Asia Pacific
Largest Market:
North America

The global plasma fractionation market size was worth USD 20,551 million in 2021. It is expected to be valued at USD 36,223 million by 2030, growing at a CAGR of 6.5% during the forecast period (2022–2030). Fractionation is a way to separate a certain amount of a mixture using a machine. Plasma is the yellowish liquid part of blood that contains blood cells. Plasma fractionation separates high-quality proteins like albumin and immunoglobulins from the rest of the plasma. These products are called plasma derivatives because they are made by separating plasma. These products are also used in different areas of medicine like neurology, hematology, critical care, and immunology. Plasma products are also used in hospitals and labs that do clinical research.

The primary factor driving the market is the rise in the geriatric population, which is more susceptible to rare diseases that need plasma derivatives for treatment. The plasma fractionation market is also growing because immunoglobulins and alpha-1-antitrypsin are used more readily in medicine worldwide. Additionally, the spike in the number of plasma collection centers around the world is a significant factor in the growth of this market.

Plasma Fractionation Market share

Get more information on this report Download Sample Report

Market Dynamics

What are the Driving Factors for the Global Plasma Fractionation Market in the Forecast Years?

  • Improved Research and Development (R&D)

More people worldwide are contracting rare diseases, which has increased the demand for plasma fractionation products. Plasma derivatives are used to treat rare diseases like Guillain-Barré and myasthenia gravis. These diseases are rare and not well understood. Therefore, there is an increased emphasis on research and development of new therapies and drugs for rare diseases, stimulating the plasma fractionation market.

  • Growing Geriatric Population

The growing geriatric population worldwide contributes to the market significantly. Older people are more susceptible to rare diseases. For example, Guillain-Barré syndrome is more prevalent in older people. Likewise, most people with thymoma get myasthenia gravis between the age of 50 and 60. This increases the demand for plasma fractionation. Consequently, the government and private organizations are working hard to inform patients about available and effective treatments, boosting market growth.

  • Increased Use of Immunoglobulins

Immunoglobulin is an antibody present in the cells of the immune system. Immunoglobulins are used to treat conditions like immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, and nervous system disorders. Immunoglobulins are also used to treat lupus and vasculitis, which are both rare diseases. Immunoglobulins like IVIG are also used to treat diseases with no alternative treatment.

Furthermore, people with Guillain-Barré syndrome, multiple myeloma, myasthenia gravis, acquired factor VIII inhibitor syndrome, autoimmune neutropenia, post-transfusion purpura, and polymyositis/dermatomyositis are often advised to take immunoglobulins. Immunoglobulins can also treat primary immunodeficiency and secondary immunodeficiency, among other things. Therefore, the growing awareness and widescale adoption of immunoglobulins in medicine spur the plasma fractionation market.

Restraints: High Costs of Plasma Derived Products

Plasma-derived products are made from donated human blood. Plasma or clotting proteins are separated from the blood and used to make clotting factor concentrates or fresh frozen plasma. Fractionation is an expensive process involving getting blood from many people and mixing it. These people go through screenings to find and prevent diseases that can be spread through plasma. Also, plasma-based products are tested again after they are made to kill any bacteria or viruses in them. Due to these steps, products made from plasma are expensive. Furthermore, products made from therapeutic plasma can cost more than USD 200,000. This slows the growth of the plasma fractionation market.

What Are Future Growth Opportunities in the Plasma Fractionation Market Globally?

  • High Growth Potential in Emerging Countries

The plasma fractionation business has immense potential in developing economies. The market in developing economies like Canada, Saudi Arabia, and others is driven by the ever-changing life science industry. Plasma fractionation is also used more in low-and middle-income countries to make medicines from plasma. For example, the World Federation of Hemophilia estimates that only 25% of people with hemophilia get the proper care worldwide. Additionally, the International Patient Organization for Primary Immune Deficiencies says immunoglobulin products are unavailable to 70% of patients with primary immune deficiencies. Therefore, the high unmet need for plasma fractionation will likely create good growth opportunities in the coming future.

 

Segmental Analysis  

The global plasma fractionation market share is segmented by product and sector.

  • By Product

Product-wise, the global plasma fractionation market is classified into Albumin and Immunoglobulins.

Immunoglobulins hold the highest market share and are expected to grow at a CAGR of 6.4% during the forecast period. Immunoglobulins are made from donated human plasma. They are important biological parts used to treat many autoimmune and inflammatory diseases. The main thing that helps the immunoglobulin segment grow is that more immune deficiencies are being found and treated. The growth of the immunoglobulin plasma fractionation market is also supported by the increasing use of high-dose IgG products to treat autoimmune neurologic diseases.

Albumin is used more in medical situations like acute liver failure and cardiopulmonary bypass. Albumin is the most common plasma protein because it makes up more than 50% of serum protein in healthy people. It is also made by the liver and is chemically insoluble in water.

  • By Sector

Sector-wise, the global plasma fractionation market is classified into Public and Private Sectors.

The Private Sector holds the maximum share and is expected to grow at a CAGR of 6.7% during the forecast period. The private sector is run by businesses for profit. It includes all businesses that are not owned or run by the government. In the private sector, companies collect plasma in highly controlled settings by licensed and trained staff. Also, these private companies keep plasma in storage for 60 days before sending it to their factories. At the manufacturing sites, therapeutic proteins are taken out of the plasma and then purified, and viruses are killed to make the products safer for patients.

Public Sector companies pay for themselves and are owned by the government. The people who work in the public sector offer services that help everyone, not just those who use them. For example, the Korean Red Cross is a non-profit group in South Korea that works with plasma fractionation, which is part of the public sector. Likewise, the Japanese Red Cross works as a non-profit plasma fractionator in Japan.

 

Regional Analysis 

The global plasma fractionation market share is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Is North America Likely to Dominate the Global Plasma Fractionation Market?

Plasma Fractionation Market Regional Analysis

Regional Growth Insights Request Sample Pages

North America holds the highest share of the plasma fractionation market and is expected to grow at a CAGR of 6.3% during the forecast period. This is because immunoglobulins and alpha-1-antitrypsin are readily used in medicines, plasma fractionation products are easily available, and many big companies offer these products. Furthermore, the government is raising awareness about plasma-derived products, propelling the market.

Significant key players in the sector, including Baxter International Inc., Emergent BioSolutions, KabaFusion, Biotest AG, and CSL Ltd, also contribute significantly to the market. Additionally, the rising incidences of rare diseases, a growing elderly population, and an increasing number of plasma collection centers further boost the demand for plasma fractionation.

Asia-Pacific is the fastest-growing region in the plasma fractionation market. It is expected to grow at a CAGR of 6.9% during the forecast period, accounting for USD 9,090 million. The presence of governmental agencies that oversee and control plasma collection, fractionation, and sales is primarily driving the market. Furthermore, hemophilia, primary & secondary immune deficiencies, and rising rates of severe fever with thrombocytopenia syndrome (SFTS) contribute to the market expansion.

In the European region, Germany, France, the UK, Italy, and Spain are looked at as some of the most important countries. In 2021, 14.4% of the global market for plasma fractionation was made up of sales in Europe. During the next few years, the European market is expected to grow steadily, owing to the growing demand for plasma fractionation products and a strong presence of key players in the industry. Another factor influencing the expansion of the plasma fractionation market is the numerous improvements made to plasma fractionation products by the leading manufacturers.

Due to the expansion of the target population, the surge in demand for plasma fractionation products, and improvements in the healthcare infrastructure, LAMEA is a rising market that is anticipated to offer lucrative growth possibilities for major players. Additionally, the rising prevalence of hemophilia and other medical diseases in LAMEA that call for the usage of plasma derivatives for therapy are increasing the use of plasma fractionation, fueling the market expansion.

 

Competitive Analysis

The major key players in the global plasma fractionation market are Grifols SA, Baxter International Inc., CSL Ltd, Bio Product Laboratory, Octapharma AG, Sanquin, Kedrion, Biotest, Takeda Pharmaceuticals, etc.

 

Recent Developments

  • May 2022- Bio Product Laboratory received authorization for orphan drug marketing for Coagadex in Mexico.
  • April 2022- Baxter highlighted the new data at SCCM Critical Care Congress showing hemodynamic monitoring.
  • April 2022- Octapharma AG partnered with local authorities to provide Ukrainian refugees housing.
  • March 2022- CSL Ltd received clearance from the FDA for the plasma collection technology.

 

Market Segmentation

By Product

  • Albumin
  • Immunoglobulins

By Sector

  • Public Sector
  • Private Sector

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
Price Starts From
$4250

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

As featured on :

Trusted by Fortune 500
Over 30000+ subscribers